GlycoMimetics, Inc. (GLYC) Announces Presentation Of Rivipansel Data In Pediatric Patients At American Society Of Pediatric Hematology Oncology 27th Annual Meeting
5/15/2014 9:55:32 AM
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that data from a Phase 2 clinical trial of its lead drug candidate rivipansel (GMI-1070) in pediatric patients has been presented at the American Society of Pediatric Hematology Oncology (ASPHO) 27th Annual Meeting. As part of the symposium entitled, “Sickle Cell Disease: Saving the Brain and Treating the Pain,” Timothy McCavit, M.D., M.S., Assistant Professor of Pediatric Hematology-Oncology at UT Southwestern Medical Center, highlighted the results observed in a randomized, multi-center, double-blind, adaptive Phase 2 study of rivipansel in pediatric sickle cell disease patients with vaso-occlusive crisis (VOC). The ASPHO Meeting is taking place May 14 through May 17 at the Palmer House Hilton in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by